Trial · NCT03200717
Results by group106
Each measurement the trial posted, group by group, in the words and numbers it posted.
61 to 80 of 106
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 3 Day 1 | -1.3 | Standard Deviation 15.58 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 4 Day 1 | -0.7 | Standard Deviation 10.88 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 3rd Line | Cycle 4 Day 1 | -1.5 | Standard Deviation 22.86 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 4 Day 1 | -0.8 | Standard Deviation 13.27 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 5 Day 1 | -1.5 | Standard Deviation 13.61 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 3rd Line | Cycle 5 Day 1 | 3.2 | Standard Deviation 19.51 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 5 Day 1 | -0.7 | Standard Deviation 14.45 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 6 Day 1 | -1.3 | Standard Deviation 18.35 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 3rd Line | Cycle 6 Day 1 | -3.5 | Standard Deviation 24.09 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 6 Day 1 | -1.7 | Standard Deviation 19.21 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 7 Day 1 | 0.2 | Standard Deviation 11.89 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 3rd Line | Cycle 7 Day 1 | 0.7 | Standard Deviation 20.37 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 7 Day 1 | 0.3 | Standard Deviation 13.73 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 9 Day 1 | 3.8 | Standard Deviation 11.64 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 9 Day 1 | 3.8 | Standard Deviation 11.64 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 11 Day 1 | 3.9 | Standard Deviation 12.62 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 3rd Line | Cycle 11 Day 1 | -2.0 | Standard Deviation NA | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 11 Day 1 | 3.5 | Standard Deviation 12.30 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | Pazopanib- 2nd Line | Cycle 13 Day 1 | 5.7 | Standard Deviation 12.26 | Score on a scale |
| Change From Baseline in EuroQoL 5-level Instrument Visual Analogue Scale (EQ-5L-5D VAS) Score | All Participants | Cycle 13 Day 1 | 5.7 | Standard Deviation 12.26 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03200717/results?page=4